COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 Nov 9, 2021
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360… Nov 9, 2021
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder Nov 3, 2021
